![Eric Sullivan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Eric Sullivan
Directeur Financier/CFO chez
Convergent Therapeutics, Inc.
Profil
Eric M.
Sullivan is currently Chief Financial Officer at Convergent Therapeutics, Inc. Former roles include Non-Executive Director at Chimeric Therapeutics Ltd. (Australia) from 2023 to 2026, Chief Accounting Officer, VP-Finance & Treasurer at Genetix Biotherapeutics, Inc. from 2016 to 2017, Chief Financial Officer at TCR² Therapeutics, Inc., President, Chief Operating & Financial Officer at Triplet Therapeutics, Inc., and Senior Vice President at Gemini Therapeutics, Inc. Education includes undergraduate studies at Bentley University.
Postes actifs de Eric Sullivan
| Sociétés | Poste | Début |
|---|---|---|
Convergent Therapeutics, Inc.
 Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops radiopharmaceutical therapies for prostate cancer | Directeur Financier/CFO | 01/09/2023 |
Anciens postes connus de Eric Sullivan
| Sociétés | Poste | Fin |
|---|---|---|
| CHIMERIC THERAPEUTICS LIMITED | Directeur/Membre du Conseil | 06/07/2026 |
| GENETIX BIOTHERAPEUTICS, INC. | Comptroller/Controller/Auditor | 04/08/2017 |
| GEMI THER | Corporate Officer/Principal | - |
Triplet Therapeutics, Inc.
 Triplet Therapeutics, Inc. Medical/Nursing ServicesHealth Services Develops therapy for huntington's , myotonic dystrophy, spin cerebellar ataxias and repeated expansion diseases | President | - |
| TCR2 THERAPEUTICS INC. | Directeur Financier/CFO | - |
Formation de Eric Sullivan
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
26
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
bluebird bio, Inc.
 bluebird bio, Inc. BiotechnologyHealth Technology Develops genetic therapies based on blood stem cells | Health Technology |
Bentley University
 Bentley University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TCR2 Therapeutics, Inc.
 TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage cell therapy company which engages in the development of biological drugs and engineering T-cells for cancer therapy | Health Technology |
Triplet Therapeutics, Inc.
Triplet Therapeutics, Inc. Medical/Nursing ServicesHealth Services Develops therapy for huntington's , myotonic dystrophy, spin cerebellar ataxias and repeated expansion diseases | Health Services |
Chimeric Therapeutics Ltd. (Australia)
 Chimeric Therapeutics Ltd. (Australia) BiotechnologyHealth Technology Develops cell therapies for the tumors | Health Technology |
Gemini Therapeutics, Inc.
 Gemini Therapeutics, Inc. BiotechnologyHealth Technology Develops drugs for dry age-related macular degeneration and associated rare genetic diseases | Health Technology |
Convergent Therapeutics, Inc.
Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops radiopharmaceutical therapies for prostate cancer | Health Technology |
